昔日“疫苗之王”科兴控股大消息：美股上市地位保住了

Core Viewpoint - The recent decision by the Nasdaq Hearing Committee allows Sinovac Biotech Ltd. to maintain its listing status on the Nasdaq Global Market, contingent upon the timely submission of financial reports by May 11, 2026 [5][6]. Group 1: Financial Reporting and Compliance - Sinovac must complete the submission of its annual financial report for the fiscal year ending December 31, 2024, and the interim financial report for the second quarter of 2025 by May 11, 2026 [6][7]. - The company has engaged Zhonghua Certified Public Accountants to conduct independent audits and is working collaboratively to meet the reporting requirements [7][8]. Group 2: Historical Performance and Challenges - Sinovac's revenue peaked in 2021 with a total revenue of 135.49 billion yuan, reflecting a year-on-year increase of 3694.36%, and a net profit of 59.21 billion yuan, up 7571.97% [9]. - However, the demand for COVID-19 vaccines has sharply declined, leading to significant revenue drops of 92.30% in 2022 and 69.97% in 2023, with net profits decreasing by 98.66% and 187.75% respectively [9]. Group 3: Product Pipeline and Market Expansion - Sinovac has a diverse product pipeline beyond COVID-19 vaccines, including vaccines for hepatitis A, influenza, varicella, and inactivated polio vaccines [9]. - Recent approvals for new products, such as the 23-valent pneumococcal polysaccharide vaccine, and successful bids for international orders, indicate a potential for growth in international markets [9]. Group 4: Governance Issues - Sinovac has faced ongoing internal governance challenges, stemming from a power struggle between co-founders, which has led to significant operational disruptions [10][11]. - The company has been under scrutiny for governance failures, resulting in its stock being suspended by Nasdaq in 2019 [12].